MedTrace Logo

Selinexor Combination Ph 1 Study

NCT05177276 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-01-04

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.

Conditions

  • Solid Tumor Malignancy

Interventions

DRUG

Selinexor

DRUG

Irinotecan

Sponsors & Collaborators

  • Hackensack Meridian Health

    collaborator OTHER

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • Martin Gutierrez

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177276 on ClinicalTrials.gov